Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Bootz

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
International Journal of Molecular Sciences|December 28, 2016
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer ProgressionAnne von Mässenhausen, Johannes Brägelmann, Hannah Billig, et al.
The American Journal of Pathology|March 21, 2015
Clinical and molecular implications of MED15 in head and neck squamous cell carcinomaDavid Adler, Anne Offermann, Rebecca Halbach, et al.
Head & Neck|August 6, 2013
Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancerAndreas Schröck, Friederike Göke, Patrick Wagner, et al.
Oncotarget|October 8, 2016
PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinomaVerena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|September 9, 2017
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinomaTim Müller, Martin Braun, Dimo Dietrich, et al.
Clinical Epigenetics|November 22, 2019
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanomaTobias A W Holderried, Luka de Vos, Emma Grace Bawden, et al.
Cardiovascular and Interventional Radiology|April 8, 2011
Endovascular treatment of epistaxis: indications, management, and outcomeKatharina Strach, Andreas Schröck, Kai Wilhelm, et al.
Targeted Oncology|April 8, 2016
Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell CarcinomaAnne von Mässenhausen, Mario Deng, Hannah Billig, et al.
Antiviral Therapy|August 6, 2011
Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonistStephan Herberhold, Christoph Coch, Thomas Zillinger, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
International Journal of Molecular Sciences|December 28, 2016
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer ProgressionAnne von Mässenhausen, Johannes Brägelmann, Hannah Billig, et al.
The American Journal of Pathology|March 21, 2015
Clinical and molecular implications of MED15 in head and neck squamous cell carcinomaDavid Adler, Anne Offermann, Rebecca Halbach, et al.
Head & Neck|August 6, 2013
Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancerAndreas Schröck, Friederike Göke, Patrick Wagner, et al.
Oncotarget|October 8, 2016
PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinomaVerena Sailer, Emily Eva Holmes, Heidrun Gevensleben, et al.
Oncotarget|September 9, 2017
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinomaTim Müller, Martin Braun, Dimo Dietrich, et al.
Clinical Epigenetics|November 22, 2019
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanomaTobias A W Holderried, Luka de Vos, Emma Grace Bawden, et al.
Cardiovascular and Interventional Radiology|April 8, 2011
Endovascular treatment of epistaxis: indications, management, and outcomeKatharina Strach, Andreas Schröck, Kai Wilhelm, et al.
Targeted Oncology|April 8, 2016
Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell CarcinomaAnne von Mässenhausen, Mario Deng, Hannah Billig, et al.
Antiviral Therapy|August 6, 2011
Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonistStephan Herberhold, Christoph Coch, Thomas Zillinger, et al.
Pageof 10